An investigation on the effects of thoracic organ transplantation with respect to pre-transplant malignancies

Abstract

Author(s): Sanjay Bhatnagar, Debrup Banerjee, Shantanu Kulkarni, Upendra Sharma Udayashankar Sulibele, Shikhar Gupta, Geetika M. Patel

Background: Organ transplantation is generally contraindicated by PreTransplant Malignancy (PTM). One healthy lung from a deceased donor is often used to replace one that is diseased, failing, or otherwise damaged in a lung transplant. Only patients who have not shown significant improvement after receiving standard medical care are acceptable for a lung transplant. Objective: The study's objective was to observe the effects of thoracic organ transplantation in connection to PTM. Methods: In our study, collected 13,603 adult patients had lung transplants. Secondary stratification was based on tumor kind, with primary stratification determined by PTM. Mortality was assessed using multivariable Cox proportional hazards regression models and matched cohorts (2:1). Results: PTM was found in 7.4% of the 640 lung transplant patients. Average annual examination of lung transplantation patients with PTM found that their subsistence amounts at 90-days, 3 years, and 7 years were similar to those of patients without PTM (p<0.05). Even after risk adjustment, these results remained. No tumor type was linked to a higher mortality rate in lung transplantation patients. Analyses of identical groups in lung transplantation patients showed equivalent results. We investigate the survival rate, risk factors, and Lungs Allocation Score (LAS) of PTM patients. Conclusion: This extensive investigation examining the impact of PTM discovered that the incidence of PTM was 5.2% in lung transplantation. PTM does not, in general, increase mortality in any group. Consequently, carefully chosen PTM patients shouldn't be denied lung transplantation.

Share this article